It was reported to improve the impaired T‐cell immune synapse in FL21 and CLL,6 to enhance the activation of CD8+ T and NK cells, and to reduce Treg cells and rebalance Th subsets.22 The BTK inhibitor ibrutinib is another candidate to help the immune normalisation, which was recently demonstrated to improve the function of T cells including modulating Th1/Th2 subsets.23 Future studies are required to examine whether patients with superior responses to lenalidomide, ibrutinib or other immunomodulatory drugs demonstrate better improvement of T‐cell immunity. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.